T
14.27
-0.40 (-2.73%)
| Previous Close | 14.67 |
| Open | 14.32 |
| Volume | 20,708 |
| Avg. Volume (3M) | 361,157 |
| Market Cap | 266,316,736 |
| Price / Book | 2.07 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 - 12 May 2025 |
| Diluted EPS (TTM) | -6.83 |
| Total Debt/Equity (MRQ) | 2.35% |
| Current Ratio (MRQ) | 12.65 |
| Operating Cash Flow (TTM) | -59.08 M |
| Levered Free Cash Flow (TTM) | -65.09 M |
| Return on Assets (TTM) | -37.71% |
| Return on Equity (TTM) | -84.79% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Tectonic Therapeutic, Inc. | Bullish | - |
AIStockmoo Score
0.5
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.50 |
|
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 37.73% |
| % Held by Institutions | 43.52% |
| 52 Weeks Range | ||
| Median | 101.00 (607.78%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 21 Mar 2025 | 101.00 (607.78%) | Buy | 21.15 |
| 31 Jan 2025 | 112.00 (684.86%) | Buy | 54.14 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 15 Apr 2025 | Announcement | Tectonic Therapeutic to Present Phase 1b Data for TX45 at European Society of Cardiology Heart Failure 2025 |
| 20 Mar 2025 | Announcement | Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights |
| 20 Feb 2025 | Announcement | Tectonic Therapeutic to Participate in March Investor Conferences |
| 03 Feb 2025 | Announcement | Tectonic Announces $185 Million Private Placement |
| 30 Jan 2025 | Announcement | Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |